Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

NGNE US Equity

Neurogene Inc.Health Care · Pharmaceutical Preparations · CIK 1404644 · FY ends Dec 31
$39.43
+3.76 (+10.54%)
USD · as of 2026-08-19 · marketstack

Legal & controls

5 of 5 annual reports readable here

Item 3 and Item 9A as filed · every verdict is the registrant’s own sentence, printed below it · a filing that fails an extraction gate reads “not extracted”

Fiscal yearFiledItem 3ICFRdisclosure controlsmaterial weaknessFiling
2025-12-312026-03-24described hereeffectivenot extractednone in Item 9AEDGAR

Item 3 · We may from time to time be named as a party to legal claims, actions and complaints, including matters involving employment, intellectual property or others. We are not presently a party to any legal proceedings that, in the opinion of our management, would reasonably be expected to have a material adverse effect on our business, financial condition, operating results or cash flows if determined adversely to us. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.

Item 9A · ICFR · Based on its evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2025.

2024-12-312025-03-24described hereeffectivenot extractednone in Item 9AEDGAR

Item 3 · We may from time to time be named as a party to legal claims, actions and complaints, including matters involving employment, intellectual property or others. We are not presently a party to any legal proceedings that, in the opinion of our management, would reasonably be expected to have a material adverse effect on our business, financial condition, operating results or cash flows if determined adversely to us. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.

Item 9A · ICFR · Based on its evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2024.

2023-12-312024-03-18described hereeffectivenot extractedremediated (prior year)EDGAR

Item 3 · From time to time, we may be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Item 9A · ICFR · Based on its evaluation under the framework in Internal Control-Integrated Framework, management concluded that our internal control over financial reporting was effective as of December 31, 2023.

Item 9A · material weakness · This email compromise attack highlighted a deficiency in our internal control over financial reporting, specifically in our controls relating to changes made to supplier payment information, which we determined amounted to a material weakness in our controls.

2022-12-312023-03-20none statedeffectivenot extractednone in Item 9AEDGAR

Item 3 · We are not currently subject to any material legal proceedings.

Item 9A · ICFR · Based on its evaluation under the framework in Internal Control—Integrated Framework, our management concluded that our internal control over financial reporting was effective as of December 31, 2022.

2021-12-312022-03-01none statedeffectivenot extractednone in Item 9AEDGAR

Item 3 · We are not currently subject to any material legal proceedings.

Item 9A · ICFR · Based on its evaluation under the framework in Internal Control—Integrated Framework, our management concluded that our internal control over financial reporting was effective as of December 31, 2021.

5 of 5 annual reports on record have their filing text cached on this host; the rest are listed with their EDGAR link and no extraction, because this surface never fetches from SEC on a page load.

  • Item 3 and Item 9A are located in the filing HTML already cached on this host and read with the same line-anchored item matcher and largest-gap body disambiguation the filing-narrative pass uses for Item 1A and Item 7 — no fetch, no model, no summarization.
  • A heading is accepted as a section only when it is not a table-of-contents row (a trailing page number), not a quoted reference in prose, and names its own section; the span must then clear a per-item length band and carry readable text after the heading. Anything that fails a gate is served as 'not extracted' with the reason — never as a default value.
  • An effectiveness conclusion is read only from a sentence that names its own control set (disclosure controls and procedures, or internal control over financial reporting) and states an outcome. Conditional sentences — the standard limitations paragraph and forward-looking remediation language — are excluded, because they are hypotheses rather than conclusions.
  • When a filing's own sentences disagree — an effective conclusion beside an unremediated material-weakness disclosure, or two conclusions of opposite sign — no verdict is asserted. A wrong 'controls were effective' reading is worse than no reading.
  • Every verdict is shown beside the verbatim sentence it was read from. The excerpt is the filing's own words, capped at 1,200 characters; the filing itself is one link away.